Pfizer will use the new site for its Cardiovascular, Metabolic and Endocrine Disease (CVMED) and Neuroscience Research Units.
PharmaTherapeutics R&D head and senior vice president Rod MacKenzie said they will provide the best environment for our researchers to invent the next generation of medicines in areas of greatest need, such as Alzheimer’s disease, schizophrenia,
The company expects to move into the new space when it is completed in the fourth quarter of 2013.